Trial Profile
Phase 2 Study of Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms MEDICARE
- 09 Mar 2020 Status changed from active, no longer recruiting to completed.
- 07 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 30 Aug 2018 Planned End Date changed from 1 Jun 2019 to 1 Mar 2020.